PerkinElmer Announces Collaboration with Rutgers University Cell and DNA Repository

Complete the form below to unlock access to ALL audio articles.
Next Generation Sequencing (NGS) research has the potential to
greatly advance knowledge and facilitate data sharing in identifying the
causes of disease, in developing potential disease therapies, as well
as in possible clinical diagnostic innovations. The combination of
PerkinElmer’s sample library automation with Rutgers’ world-renowned
biorepository will make millions of biological samples accessible to
researchers worldwide, to help enable large-scale genomic and
disease-related studies.
The PerkinElmer NGS laboratory pipeline preparation solutions will
enable the Rutgers University Cell and DNA Repository (RUCDR) to perform
quality control (QC) on 25,000 DNA samples per week, and prepare
hundreds of DNA and RNA sequence libraries per week. The products in use
include:
• Sciclone® NGS Workstation – automated solution for high-throughput
sequencing sample preparation, to be used for library preparation and
RNA sequencing.
• LabChip® GX Nucleic Acid Separations System – microfluidics system,
to be used for RNA sample quality control and DNA library quality
control.
• LabChip® DS Microplate Reader – to be used for quality control of extracted biological material.
• Twister® II Microplate Handler – a high capacity plate stacker, to feed biological samples through the LabChip DS reader.
Kevin Hrusovsky, president, Life Sciences & Technology, PerkinElmer,
said, “PerkinElmer is very proud to be selected by Rutgers for this
milestone project in revolutionizing Next Generation Sequencing
research. We are excited to be collaborating with a true pioneer in the
field of biobanking for NGS as Rutgers makes its millions of samples
available to fuel the life sciences research community’s fastest growing
and most exciting technique for basic biological research and disease
research.”
Dr. Andrew Brooks, associate professor of genetics and chief operating
officer, Rutgers University Cell and DNA Repository, said, “Going
forward, the RUCDR will have the capacity to prepare every biological
sample coming into the repository for automated sequencing applications.
This will help expedite research projects, ensure comparable data
quality across analytical centers, and facilitate large-scale access and
use of clinically-relevant samples across a variety of NIH, foundation
and industry funded projects. As preserving prepared libraries of
patient samples is becoming a new standard practice for accelerating NGS
studies, it is our intention to continue to be the leader in providing
researchers with unparalleled access to high quality nucleic acid and
cellular material to make potential therapies and diagnostics more
powerful and accurate. Without this critical relationship with
PerkinElmer, we would not have been able to achieve these goals as
efficiently as we have.”